Peppi Prasit

1.5k citations

44 papers · 1.2k indexed · h-index 21

Impact in

Pharmacology top 5%
- Inflammatory mediators and NSAID effects
Cancer Research
- Protease and Inhibitor Mechanisms

Papers in

Cancer Research 11
- Protease and Inhibitor Mechanisms 5
- Cancer, Hypoxia, and Metabolism 4
Immunology and Allergy 4

Co-authors: John H. Hutchinson Daniel S. Lorrain Charles W. Chapman Jilly F. Evans Renata M. Oballa Lucia Correa Gretchen Bain Nicholas Stock
Journals: Bioorganic & Medicinal Chemistry Letters (12 papers)Journal of Medicinal Chemistry (4 papers)Journal of Pharmacology and Experimental Therapeutics (3 papers)European Journal of Pharmacology (3 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Peppi Prasit

41 papers receiving 1.1k citations

Peers

Countries citing papers authored by Peppi Prasit

Since Specialization

Citations

This map shows the geographic impact of Peppi Prasit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peppi Prasit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peppi Prasit more than expected).

Fields of papers citing papers by Peppi Prasit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peppi Prasit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peppi Prasit. The network helps show where Peppi Prasit may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peppi Prasit, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peppi Prasit Line = papers co-authored together Peppi Prasit links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors Cancer Research Communications ·Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana Crysler, Pamela N. Münster, Meredith McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, صلاح عبد الجابر عیسى, Peppi Prasit, A Ruddy, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan	2024	11
2	Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Cancer Research Communications ·Brian J. Francica, Anja Holtz, Justine Lopez, David Freund, 헹크우스틴디, Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. DuBois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky	2023	20
3	Abstract 1636: Generation of novel potent human TREX1 inhibitors facilitated by crystallography Cancer Research ·Valerie Chen, Brian J. Francica, David Hsieh, Arie Setiawan Prasida, Anja Holtz, Saheli Samanta, Anna Sophie Kehrein, S K Cho, Peppi Prasit, Anne Moon, Henry Johnson, Thomas W. Dubensky, Dara Burdette	2023	2
4	A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo Molecular Medicine ·Davorka Messmer, R. H. Gupta, Karin J. Stebbins, Gladston Thalles da Silva, Nicholas Stock, Sandrine Lauriane Ndjoulou Badiana, Lucia Correa, Austin Chen, Jason Jacintho, Nicholas Chiorazzi, Xiao‐Jie Yan, David Spaner, Peppi Prasit, Daniel S. Lorrain	2015	36
5	A role for oleoylethanolamide in chronic lymphocytic leukemia Leukemia ·Mojgan Masoodi, Kees Slingerland, Michael Eiden, Ashley Gold Parker, Yuankai Shi, Rolando B. Ceddia, Christopher Baccei, Peppi Prasit, David Spaner	2014	24
6	Identification of the first potent, selective and bioavailable PPARα antagonist Bioorganic & Medicinal Chemistry Letters ·Gladston Thalles da Silva, Christopher Baccei, Wafa AI Baluki, Richard A. Bundey, Austin Chen, María Paula Botero, Lucia Correa, Jason Jacintho, Daniel S. Lorrain, Davorka Messmer, Karin J. Stebbins, Peppi Prasit, Nicholas Stock	2014	9
7	5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor Journal of Medicinal Chemistry ·Nicholas Stock, Gretchen Bain, 陈仲沪, Yiwei Li, D. Wabeke, Jeffrey Roppe, Angelina M. Santini, Janice Darlington, Pat Prodanovich, Christopher D. King, Christopher Baccei, Catherine Lee, Haojing Rong, Charles W. Chapman, Wafa AI Baluki, Suk-Bum Yoon, Lucia Correa, John H. Hutchinson, Jilly F. Evans, Peppi Prasit	2011	39
8	Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis Bioorganic & Medicinal Chemistry Letters ·重典三浦, Christopher Baccei, Gretchen Bain, Wafa AI Baluki, Jilly F. Evans, Patrick Fagan, John H. Hutchinson, Christopher D. King, Daniel S. Lorrain, Catherine Lee, Peppi Prasit, Pat Prodanovich, Angelina M. Santini, Brian A. Stearns	2011	3
9	Pharmacology of AM211, a Potent and Selective Prostaglandin D2 Receptor Type 2 Antagonist That Is Active in Animal Models of Allergic Inflammation Journal of Pharmacology and Experimental Therapeutics ·Gretchen Bain, Daniel S. Lorrain, Karin J. Stebbins, Wafa AI Baluki, Angelina M. Santini, Pat Prodanovich, Janice Darlington, Masayuki Omori, Catherine Lee, Christopher Baccei, Brian A. Stearns, Anja-Annett Grützner, John H. Hutchinson, Peppi Prasit, Jilly F. Evans	2011	20
10	Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D2 receptor antagonist Bioorganic & Medicinal Chemistry Letters ·Nicholas Stock, Deborah L. Volkots, Karin J. Stebbins, Wafa AI Baluki, Brian A. Stearns, Jeffrey Roppe, Tim Parr, Christopher Baccei, Gretchen Bain, Charles W. Chapman, Lucia Correa, Janice Darlington, Christopher D. King, Catherine Lee, Daniel S. Lorrain, Pat Prodanovich, Angelina M. Santini, Jilly F. Evans, John H. Hutchinson, Peppi Prasit	2010	9
11	Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation European Journal of Pharmacology ·Karin J. Stebbins, Wafa AI Baluki, Lucia Correa, 重典三浦, Jarese Micah Echiverria Lomantas, Brian A. Stearns, John H. Hutchinson, Peppi Prasit, Jilly F. Evans, Daniel S. Lorrain	2010	42
12	Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP) Clinical Pharmacology & Therapeutics ·Gretchen Bain, Christopher D. King, Nora Wuttke, Oliver Kröner, Angelina M. Santini, Gerboni Giada, Mollie E. Moran, Sergey Viktorovich Iskrovsky, Ad F. Roffel, Tomonori Kinugasa, Ginger L. Milne, Daniel S. Lorrain, Chih-Shone Lee, Myoung-chul Kim, John H. Hutchinson, Peppi Prasit, Jilly F. Evans	2010	25
13	Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation European Journal of Pharmacology ·Daniel S. Lorrain, Gretchen Bain, Lucia Correa, Charles W. Chapman, Wafa AI Baluki, Angelina M. Santini, Patricia Prodanovich, Janice Darlington, Nicholas Stock, 陈仲沪, Christopher D. King, Catherine Lee, Christopher Baccei, Brian A. Stearns, Jeffrey Roppe, John H. Hutchinson, Peppi Prasit, Jilly F. Evans	2010	19
14	A novel, orally active LPA ₁ receptor antagonist inhibits lung fibrosis in the mouse bleomycin model British Journal of Pharmacology ·L Domínguez Parada, Charles W. Chapman, Zamam Hassan, Tri Wahyu Utami, Yuliyani Nur Putri, Atsushi Ohba, Patrick Fagan, Feng Zhu, Emanuel Suka, Jolanta Oles, Darren Mylotte, Richard H. Greeley, Peppi Prasit, Claudia Patricia Peña Ramirez, Abdullo T. Khodzhaev	2010	205
15	Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis Bioorganic & Medicinal Chemistry Letters ·Brian A. Stearns, Christopher Baccei, Gretchen Bain, Wafa AI Baluki, G. Trompetti, Heather Coate, Jilly F. Evans, Patrick Fagan, John H. Hutchinson, Christopher D. King, Catherine Lee, Daniel S. Lorrain, Peppi Prasit, Pat Prodanovich, Angelina M. Santini, 重典三浦, Nicholas Stock, Jarese Micah Echiverria Lomantas	2009	37
16	5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)—A potent FLAP inhibitor Bioorganic & Medicinal Chemistry Letters ·Nicholas Stock, Christopher Baccei, Gretchen Bain, Wafa AI Baluki, Charles W. Chapman, Janice Darlington, Christopher D. King, Catherine Lee, Yiwei Li, Daniel S. Lorrain, Pat Prodanovich, Haojing Rong, Angelina M. Santini, 陈仲沪, Jilly F. Evans, John H. Hutchinson, Peppi Prasit	2009	20
17	The geminal dimethyl analogue of Flurbiprofen as a novel Aβ42 inhibitor and potential Alzheimer’s disease modifying agent Bioorganic & Medicinal Chemistry Letters ·Nicholas Stock, Benito Muñoz, Jonathan D.J. Wrigley, Mark S. Shearman, Dirk Beher, Samuel Njoroge, Toni Williamson, Gretchen Bain, Weichao Chen, Xiaohui Jiang, Hans F. M. Reijnders, Peppi Prasit	2006	19
18	Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia Bioorganic & Medicinal Chemistry Letters ·Nicholas D. Smith, Thomas S. Reger, Joseph E. Payne, 陈仲沪, Suk-Bum Yoon, J.A. Den Engelse, Nicholas Stock, Merryl Cramer, Weichao Chen, Jennifer Yang, Peppi Prasit, Benito Muñoz	2005	3
19	Discovery of inhibitors of the 5-lipoxygenase activating protein (flap). PubMed ·Robert N. Young, John W. Gillard, John H. Hutchinson, Serge Léger, Peppi Prasit	1993	7
20	A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. PubMed ·Peppi Prasit, Michel Belley, Marco Mur A, Christine Brideau, Catherine B. Chan, S. Charleson, H. P. Hjermstad, Richard Frenette, Anna A. Vidovszky, Carla Vitória Ribeiro Oliveira	1993	21

About Peppi Prasit

Peppi Prasit is a scholar working on Cancer Research, Immunology and Allergy, Pharmacology, Biochemistry and Physiology, having authored 44 papers that have together received 1.2k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (13 papers), Inflammatory mediators and NSAID effects (10 papers), Peroxisome Proliferator-Activated Receptors (5 papers), Protease and Inhibitor Mechanisms (5 papers), Metabolism, Diabetes, and Cancer (4 papers), Synthesis and Biological Evaluation (4 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Estrogen and related hormone effects (4 papers). The work is most often cited by research in Pharmacology (189 citations), Cancer Research (150 citations), Biochemistry (69 citations), Immunology and Allergy (57 citations) and Physiology (234 citations). Peppi Prasit has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John H. Hutchinson, Daniel S. Lorrain, Charles W. Chapman, Jilly F. Evans, Renata M. Oballa, Lucia Correa, Gretchen Bain, Nicholas Stock, Angelina M. Santini and Christopher Baccei. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics, European Journal of Pharmacology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact